RxDoctor Payments Data

James Schwender, MD

Orthopedic Surgery · Minneapolis, MNNPI 1558302372

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $3,688,626 of the $3,705,342 with a category attached, or 99.5%. Medtronic accounts for 87.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $1,105,031 and has fallen 80.9% since, to $210,686 in 2025.

$3,705,342in general payments, 2019–2025

Across 83 payments — averaging $44,643 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3.2M
  • Stryker$461K
  • Orthofix Medical, Inc.$16K
  • Curiteva, Inc.$256
  • Ossdsign USA Incorporated$206
  • Cerapedics Inc.$130
  • plus $293 from 4 others
$9,045in research payments, 2019–2025

Across 2 payments — averaging $4522.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orthofix Medical, Inc.$9K

What the payments were for

  • Royalty or licence$3,688,626100%
  • Consulting fees$14,6250%
  • Travel & lodging$1,0240%
  • Food & beverage$9380%
  • Education$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)45$3,227,703
Stryker6$460,959
Orthofix Medical, Inc.12$15,796
Curiteva, Inc.2$256
Ossdsign USA Incorporated2$206
Cerapedics Inc.12$130
Curasan, Inc.1$123
Axis Spine Technologies Inc.1$110
Johnson & Johnson1$40
Carlsmed, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few orthopedic surgery providers in Minnesotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$172,283
Medicare patients
208
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin33$502
Methylprednisolone24$179
Methocarbamol45$173

Paid to pharmacies, not to this prescriber.

Other orthopedic surgery in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →